slide1 l.
Skip this Video
Loading SlideShow in 5 Seconds..
DESERT ( D rug- E luting S tent E vent R egistry of T hrombosis) PowerPoint Presentation
Download Presentation
DESERT ( D rug- E luting S tent E vent R egistry of T hrombosis)

Loading in 2 Seconds...

play fullscreen
1 / 27

DESERT ( D rug- E luting S tent E vent R egistry of T hrombosis) - PowerPoint PPT Presentation

  • Uploaded on

DESERT ( D rug- E luting S tent E vent R egistry of T hrombosis). The International FDA approved DES Thrombosis Registry. Ron Waksman, MD and Martin Leon, MD On Behalf of the DESERT Investigators. Grant/Research Support Consulting Fees/Honoraria. Volcano Medtronic Vascular

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'DESERT ( D rug- E luting S tent E vent R egistry of T hrombosis)' - lana

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

DESERT(Drug-Eluting Stent Event Registry of Thrombosis)

The International FDA approved

DES Thrombosis Registry

Ron Waksman, MD and Martin Leon, MD

On Behalf of the DESERT Investigators

disclosure statement of financial interest
Grant/Research Support

Consulting Fees/Honoraria


Medtronic Vascular

Abbott Vascular

Boston Scientific



Abbott Vascular

Boston Scientific

Lilly Daiichi

Astra Zeneca

Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship


This is an investigator initiated trial sponsored in part by Medtronic Vascular

Acute and subacute DES thrombosis are the most devastating complication of coronary stent implantation

Late DES thrombosis is a relatively new and poorly studied phenomenon

Cohort-based analyses require years of follow-up, and very large numbers of patients


DES Thrombosis

Most have not included angiographic and procedural data

Limited number of stent thrombosis events (frequency of 2% or less):

Ability to assess only very strong correlates

Wide confidence intervals around risk estimates

A study of 5000 patients would only have approximately 100 events, with ability to reliably assess 5-10 predictors


Limitations of Prior Analyses

desert study objectives
DESERT: Study Objectives
  • To describe the correlates (clinical, procedural, and angiographic) of late (FDA approved) DES thrombosis (>30 days from stent implantation) using an adequately sized and powered case-control study design
    • 500 total late Stent thrombosis events
  • To describe the outcomes of patients with stent thrombosis in the DES era
trial design
Trial Design
  • Case Inclusion Criteria:
    • Subject >18 yo
    • Definite late/very late ST per ARC definition
    • Implanted with DES since 4/2003

Consecutive prospective enrollment

Multicenter Case-Control 1:1 Study

Limited Matching for the Site and

± 3 days to thrombosis event



DES Implant(s)

DES Implant(s)

> 30 days from implant; no acute or subacute thombosis

ST Event

  • Control Inclusion Criteria:
    • Subject >18 yo
    • No known ST per ARC definition
    • Implanted with DES since 4/2003


Subset of Pts

  • 30 days
  • 180 days
  • 365 days


Data Lock 26 OCT 2011

time to st event presentation
Time to ST Event Presentation

1 year

75% of ST after 1 yr

  • Prevalence of Late and Very Late DES ST cannot be assessed
  • In DESERT 90% of the patients in both groups had first generation DES
  • This analysis only identifies patients who survived the acute event of ST and presented for an angiogram
  • Angiographic data is currently being analyzed
  • DESERT is the largest case-control registry of late and very late DES Stent Thrombosis
  • In DESERT, the majority of the Late ST occurred after one year (~75%) and continued to occur up to 7.3 years
  • The clinical presentation of late ST was mainly MI (66.9% STEMI and 22% NSTEMI)
  • Nearly 30% of the patients with L ate ST were on DAPT at the time of the event
  • In hospital mortality of patients who presented with late ST was 3.8% and 1.67% at one year
  • Patients who had first generation DES continue to be at risk for late stent thrombosis up to 7 years
  • Younger patients, smokers, black ethnicity, patients with multi vessel disease, STEMI, or SVG lesions are at higher risk of developing late ST and should be reconsider for DES, or for a potent or longer DAPT regimen
  • Mortality with late ST is lower when compared with historically reported acute and subacute ST. This suggest a different pathological mechanism for late ST: (late restenosis and/or neo-atherosclerosis)